Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
View original at globenewswire.comRoivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roiv…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
We remain well-positioned to generate shareholder value
80% confidenceBrepocitinib Phase 3 data in dermatomyositis generated earlier this year represents a significant step forward for patients in need
80% confidenceRoivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years
80% confidenceWe have an opportunity for three meaningful first-in-class commercial launches over the next three years
80% confidenceWe are at transformational moment for Roivant
80% confidenceWe have a unique opportunity to execute on three major potential products, each of which represents a pipeline-in-a-product opportunity, each with multiple blockbuster-potential indications
80% confidenceWe have accelerated timing guidance for topline readouts in three significant programs
80% confidenceRoivant cash balance continues to support runway into profitability
80% confidenceImmunovant financing extends Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease
80% confidence